Latest Headlines

Latest Headlines

Samsung and Biogen verge on EU approval with an Enbrel biosimilar

Samsung Bioepis is months away from winning European clearance to market a copy of Amgen and Pfizer's blockbuster rheumatoid arthritis treatment Enbrel, securing a positive recommendation from EU regulators.

Novartis targets Amgen's Enbrel with second biosimilar app

Right now, Novartis' Sandoz has the only biosimilar on the U.S. market. And it's looking to make it two.

Amgen wraps up Aranesp, Enbrel marketing probe with $71M state-level settlement

Amgen is paying up to resolve claims that it broke the rules while marketing anemia drug Aranesp and anti-inflammatory blockbuster Enbrel. The company has settled with 48 states for $71 million, marking the latest state-level crackdown on alleged marketing violations in the pharma industry. 

KKR steps in to back $55M C round for biosimilars developer Coherus

Just months after inking a $246 million development deal with Baxter for a biosimilar of Enbrel, Redwood City, CA-based Coherus has rounded up a whopping $55 million C round, including cash from KKR.

Kindred to scale back animal research

The company will reformulate drugs already approved for humans and market them for pets, and expects FDA approval for three drugs for dogs by the end of the year.

The 10 best-selling drugs of 2013

It is the big sellers, the blockbusters--no, megablockbusters--that drug execs aspire to develop. And a look at the top 10 best-selling drugs globally can't help but impress with its big numbers.

Top 10 rheumatoid arthritis drugs 2013

Humira is the world's best-selling drug, bringing in $9.6 billion last year. The way drug information specialist EvaluatePharma sees it, AbbVie's ($ABBV) gem is going to remain the...

Report: Seattle biotech VLST unloads assets and shuts doors

A 9-year run for VLST has ended. The Seattle biotech outfit has peddled assets to undisclosed buyers for undisclosed terms and shut its doors for good, Xconomy 's Luke Timmerman reported.

UPDATED: Top Novartis blockbuster prospect whips Enbrel in psoriasis showdown

Novartis says that one of its top Phase III drug prospects beat out Enbrel in a head-to-head showdown on psoriasis. Investigators say that the anti-IL17A secukinumab (AIN457) nabbed all the primary and secondary endpoints in the study.

Cheaper generic combo found as effective in RA as blockbuster Enbrel

Amgen was delivered a nasty surprise about its superblockbuster Enbrel this week when a new study found that a cocktail of generics already on the market was as effective at treating rheumatoid arthritis.